Wall Street Hates These 2 Biotechs
Jan 17th 2013 4:39PM
Updated Jan 17th 2013 5:05PM
Brean Capital has come out today with a pair of substantial downgrades. First, it has downgraded VIVUS , maker of the obesity drug Qsymia, to a sell, and set the price target at a painful $7 per share. This is a 50% downside from yesterday's $14.32; the stock fell 5% as a result. Brean also downgraded Celsion to a sell, placing the price target at an astonishing $1 per share. Celsion is also down over 5% on the news. In this video, Motley Fool health-care analyst David Williamson tells us what was behind these killer downgrades, and whether investors should be worried.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense, but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health-care writer on the job, so make sure to secure a copy today by clicking here now.
The article Wall Street Hates These 2 Biotechs originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.